title: [Fatal subfulminant hepatitis during treatment with alpidem (Ananxyl)].
authors.forename: J
authors.initials: J
authors.lastname: Barki
authors.forename: D
authors.initials: D
authors.lastname: Larrey
authors.forename: G
authors.initials: G
authors.lastname: Pageaux
authors.forename: G
authors.initials: G
authors.lastname: Lamblin
authors.forename: J L
authors.initials: JL
authors.lastname: Gineston
authors.forename: H
authors.initials: H
authors.lastname: Michel
mesh_terms: D000368:Aged; D014151:Anti-Anxiety Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy; D001247:Asthenia / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000209:etiology*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D008111:Liver Function Tests; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D014151:Anti-Anxiety Agents; D007093:Imidazoles; D011725:Pyridines; C052036:alpidem
vernacular_title: Hépatite subfulminante mortelle lors d'un traitement comportant de l'alpidem (Ananxyl).